Company news

BioPorto A/S news in 2026

BioPorto A/S's news releases, calls and decks from 2026, newest first.

View company

Unlocking the Growth - Invitation to BioPorto's investor meeting on October 7

September 28, 2026

First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.

September 16, 2026

BioPorto announces Interim Results for the Second Quarter and First half of 2026

August 20, 2026

BioPorto A/S to host an investor webcast on the results for the first half of 2026

August 12, 2026

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

June 9, 2026

BioPorto announces Interim Result for the First Quarter of 2026

May 21, 2026

Resolutions of the Annual General Meeting

April 24, 2026

Grant of Warrants

April 14, 2026

Major Shareholder Announcement

April 13, 2026

BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC

April 8, 2026

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis

March 31, 2026

Notice convening the Annual General Meeting in BioPorto A/S

March 26, 2026

BioPorto announces the Annual Report for 2025

March 26, 2026

BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026

March 18, 2026

BioPorto A/S Appoints Chief Financial Officer

February 9, 2026

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update

February 5, 2026

Decks in 2026